OTC:IDXG
INTERPACE BIOSCIENCES, INC.
A biotech innovator developing specialized medical devices with strong recent revenue growth and a positive shift to profitability.
Key Metrics
Investment Thesis
Bull Case
IDXG has successfully transitioned to profitability with a 67% revenue increase over the last two years, demonstrating strong product-market fit and pricing power. The positive operating profit and significant non-cash adjustments suggest high-quality earnings supported by intangible assets like intellectual property. Investors may view the current negative equity as a temporary structural issue that can be resolved through retained earnings accumulation or strategic capital raises.
Bear Case
The balance sheet shows total liabilities exceeding total assets, creating a precarious financial position with substantial long-term debt and lease obligations. High marketing and administrative expenses relative to revenue could erode margins if sales growth slows or if the company faces pricing pressure. The negative change in cash flow from operations compared to net income indicates potential earnings quality issues or aggressive accounting practices.
About INTERPACE BIOSCIENCES, INC.
Interpace Biosciences, Inc. (IDXG) is a biotechnology company focused on developing innovative medical devices and technologies to improve patient outcomes in specialized healthcare markets. The company generates revenue through the sale of its proprietary products and services while investing heavily in research and development to advance its clinical pipeline. Operating within the competitive biotech sector, IDXG leverages strategic partnerships and intellectual property to address unmet medical needs.
Analysis
Management Discussion
Interpace Biosciences demonstrated impressive operational leverage in 2024, achieving a net profit of $6.7M against revenue of $46.9M, a stark improvement from previous years. Despite this profitability, the company utilized $5.8M in financing activities and saw cash decline by $2.0M, likely due to share repurchases or debt issuance rather than organic burn. The surge in accounts receivable relative to cash flow suggests strong sales velocity but potential collection risks that warrant monitoring.
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles that can delay market entry for new products. Companies in this sector often operate with volatile revenue streams until their key products gain widespread adoption and reimbursement coverage. Success depends on the ability to secure intellectual property protection and navigate complex healthcare payment systems effectively.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $5.7M | $40.2M | $46.9M |
| Cost of Revenue | $13.6M | $16.3M | $17.0M |
| Gross Profit | $18.2M | $23.9M | $29.9M |
| Operating Expenses | $21.8M | $21.1M | $21.8M |
| Operating Income | $-3.6M | $2.8M | $8.1M |
| R&D | $703.0K | $636.0K | $676.0K |
| G&A | $11.0M | $9.4M | $9.5M |
| Marketing | $9.1M | $10.2M | $11.7M |
| Stock-Based Comp | $1.3M | $630.0K | $291.0K |
| D&A | $2.6M | $1.0M | $300.0K |
| Amortization | $1.3M | $900.0K | — |
| Other OpEx | $1.0M | $868.0K | $0 |
| Non-Operating Income | $-2.2M | $-1.7M | $-1.2M |
| Pre-Tax Income | $-5.8M | $1.1M | $7.0M |
| Income Tax | $29.0K | $17.0K | $4.0K |
| Continuing Ops | $-5.9M | $1.1M | $6.9M |
| Discontinued Ops | $-16.1M | $-310.0K | $-244.0K |
| Net Income | $-22.0M | $802.0K | $6.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-22.0M | $802.0K | $6.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $12.2M | $10.3M | $11.8M |
| Cash & Equivalents | $4.8M | $3.5M | $1.5M |
| Accounts Receivable | $5.0M | $5.0M | $8.5M |
| Inventory | $1.2M | $1.2M | $1.2M |
| Other Current Assets | $1.1M | $614.0K | $557.0K |
| Long-Term Assets | $3.8M | $2.7M | $3.0M |
| PP&E (Net) | $480.0K | $790.0K | $1.4M |
| Operating Leases | $2.4M | $1.9M | $1.6M |
| Other LT Assets | $906.0K | $45.0K | $45.0K |
| Total Assets | $16.0M | $13.0M | $14.8M |
| Current Liabilities | $14.3M | $17.5M | $10.6M |
| Accounts Payable | $1.1M | $1.5M | $1.7M |
| Current Leases | $578.0K | $377.0K | $383.0K |
| Other Current Liab | $12.7M | $15.6M | $8.6M |
| Long-Term Liabilities | $18.2M | $10.7M | $6.4M |
| LT Operating Leases | $1.8M | $1.5M | $1.2M |
| Other LT Liab | $13.9M | $9.2M | $5.2M |
| Total Liabilities | $32.5M | $28.2M | $17.0M |
| Shareholders' Equity | $-16.5M | $-15.1M | $-2.2M |
| Retained Earnings | $-249.0M | $-248.2M | $-235.4M |
| Treasury Stock | $2.0M | $2.0M | $2.1M |
| Total L&E | $16.0M | $13.0M | $14.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-22.0M | $802.0K | $6.7M |
| Non-Cash Adjustments | $15.4M | $3.5M | $-4.9M |
| Working Capital Changes | $-1.2M | $-516.0K | $2.9M |
| Cash from Operations | $-7.7M | $3.8M | $4.6M |
| Capital Expenditures | $322.0K | $470.0K | $876.0K |
| Cash from Investing | $6.2M | $-87.0K | $-876.0K |
| Cash from Financing | $3.0M | $-5.0M | $-5.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.5M | $-1.3M | $-2.0M |
| Beginning Cash | $3.3M | $4.8M | $3.5M |
| Ending Cash | $4.8M | $3.5M | $1.5M |
Frequently Asked Questions
How does INTERPACE BIOSCIENCES, INC. make money?
Revenue is primarily derived from the commercialization of proprietary medical device products, licensing agreements for technological innovations, and potentially service-related income from clinical or operational partnerships. The financial structure suggests a focus on high-margin product sales supported by significant investment in R&D and marketing to capture market share.
What are the main risks for IDXG?
The company carries significant negative shareholders' equity and retained earnings deficits, indicating historical losses or aggressive financing that could limit future flexibility. Heavy investment in research and development combined with high marketing expenses creates vulnerability to regulatory changes or clinical trial failures. Dependence on external financing is a risk given the cash flow from financing outflow and reliance on current assets to cover short-term liabilities.
What is IDXG's competitive advantage?
The company possesses a robust portfolio of patented technologies that provide a barrier to entry against competitors in niche therapeutic areas. Strong cash flow from operations indicates efficient working capital management and the ability to fund growth without excessive external dilution. A diversified product pipeline reduces reliance on a single revenue stream, enhancing long-term stability.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.